Dr. Paul Grint is a biopharmaceutical executive and entrepreneur. He has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. Dr. Grint has had a long-standing interest in helping identify and applying novel technologies to advance diagnostics and precision medicine technologies to significantly improve patient outcomes.
Dr. Grint holds a bachelor’s degree from St. Mary’s Hospital College, University of London and a medical degree from St. Bartholomew’s Hospital College, University of London. He is currently Executive Chairman of CRISPRQC and Codagenix also a board member at Persephone Biosciences. In addition he is an Entrepreneur in Residence at UCSD supporting exciting new scientific advances in healthcare.